{"id":"verapamil-injection","safety":{"commonSideEffects":[{"rate":"10-15%","effect":"Constipation"},{"rate":"3-8%","effect":"Dizziness"},{"rate":"2-5%","effect":"Headache"},{"rate":"2-5%","effect":"Hypotension"},{"rate":"1-3%","effect":"Bradycardia"},{"rate":"1-3%","effect":"Fatigue"},{"rate":"1-2%","effect":"Edema"}]},"_chembl":null,"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"Verapamil is a non-dihydropyridine calcium channel blocker that inhibits the inward movement of calcium ions through L-type calcium channels in the heart and blood vessels. This action decreases myocardial contractility, slows atrioventricular (AV) node conduction, and causes vasodilation, resulting in reduced heart rate, blood pressure, and cardiac workload.","oneSentence":"Verapamil blocks L-type calcium channels in cardiac and vascular smooth muscle, reducing calcium influx and slowing electrical conduction.","_ai_confidence":"high"},"_scrapedAt":"2026-03-28T00:15:14.991Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Supraventricular tachycardia (acute termination and rate control)"},{"name":"Atrial fibrillation with rapid ventricular response"},{"name":"Hypertension"},{"name":"Angina pectoris"}]},"trialDetails":[{"nctId":"NCT07061574","phase":"PHASE1, PHASE2","title":"A Randomized Phase 1/2 Trial of Low Dose Anti-thymocyte Globulin (ATG) With Subsequent Adalimumab or Verapamil in New Onset Type 1 Diabetes","status":"RECRUITING","sponsor":"City of Hope Medical Center","startDate":"2026-03-30","conditions":"Type 1 Diabetes, New Onset","enrollment":120},{"nctId":"NCT07420166","phase":"NA","title":"Comparison of Intralesional Triamcinolone Acetonide Treatment With Intralesional Verapamil Hydrochloride in Keloids","status":"COMPLETED","sponsor":"Muhammad Aamir Latif","startDate":"2025-01-01","conditions":"Keloid","enrollment":60},{"nctId":"NCT01996436","phase":"PHASE4","title":"The Intra-arterial Vasospasm Trial","status":"TERMINATED","sponsor":"Peng Roc Chen, MD","startDate":"2016-08-29","conditions":"Cerebral Vasospasm","enrollment":92},{"nctId":"NCT06897969","phase":"PHASE4","title":"Comparison of Intralesional Triamcinolone Versus Verapamil for Keloid Treatment","status":"NOT_YET_RECRUITING","sponsor":"Nishtar Medical University","startDate":"2025-04-01","conditions":"Keloid Scars","enrollment":60},{"nctId":"NCT06717685","phase":"PHASE3","title":"Efficacy of Adenosine as Compared to Verapamil in Paroxysmal Supraventricular Tachycardia (pSVT) Patients","status":"RECRUITING","sponsor":"Rashid Latif Medical College","startDate":"2024-10-28","conditions":"Supraventricular Tachycardia (SVtach)","enrollment":210},{"nctId":"NCT04318990","phase":"NA","title":"DIstal vs Proximal Radial Artery Access for Cath","status":"COMPLETED","sponsor":"Baylor Research Institute","startDate":"2020-03-06","conditions":"Coronary Angiography, Coronary Angioplasty","enrollment":300},{"nctId":"NCT04573751","phase":"NA","title":"The EPIVER Randomized Controlled Trial","status":"COMPLETED","sponsor":"Tomsk National Research Medical Center of the Russian Academy of Sciences","startDate":"2020-12-30","conditions":"ST Elevation Myocardial Infarction, Percutaneous Coronary Intervention, No-Reflow Phenomenon","enrollment":104},{"nctId":"NCT05855070","phase":"NA","title":"Intralesional Hyaluronic Acid and Verapamil Injection in Peyronie's Disease","status":"UNKNOWN","sponsor":"Benha University","startDate":"2023-05-20","conditions":"Peyronie's Disease, Hyaluronic Acid, Verapamil","enrollment":42},{"nctId":"NCT05446116","phase":"NA","title":"Transfemoral Versus Transradial Partial Splenic Artery Embolization in Patients With Hypersplenism","status":"COMPLETED","sponsor":"Zagazig University","startDate":"2019-06-01","conditions":"Hypersplenism","enrollment":112},{"nctId":"NCT03102190","phase":"PHASE1","title":"Trial of Topical Verapamil in Chronic Rhinosinusitis With Nasal Polyps","status":"TERMINATED","sponsor":"Benjamin Bleier","startDate":"2017-06-05","conditions":"Sinusitis, Nasal Polyps","enrollment":6},{"nctId":"NCT03570281","phase":"PHASE2, PHASE3","title":"Edoxaban for the Treatment of Coagulopathy in Patients With Active Cancer and Acute Ischemic Stroke: a Pilot Study. (ENCHASE Study)","status":"UNKNOWN","sponsor":"Samsung Medical Center","startDate":"2018-06-15","conditions":"Correction of Cancer-related Coagulopathy With Novel Oral Anticoagulant (Edoxaban)","enrollment":40},{"nctId":"NCT02527993","phase":"PHASE4","title":"Treatment of Hypoglycemia Following Gastric Bypass Surgery","status":"COMPLETED","sponsor":"Zealand University Hospital","startDate":"2015-10","conditions":"Hypoglycemia, Obesity, Surgery","enrollment":11},{"nctId":"NCT03033537","phase":"","title":"Intracavernosal Injection of Papaverine/Verapamil Versus Papaverine/Phentolamine in Erectile Dysfunction","status":"COMPLETED","sponsor":"Adam International Hospital","startDate":"2015-07-01","conditions":"Erectile Dysfunction","enrollment":20},{"nctId":"NCT01720056","phase":"PHASE4","title":"Verapamil vs Steroid to Prevent Keloid Recurrence","status":"TERMINATED","sponsor":"The University of Western Australia","startDate":"2012-10","conditions":"Keloid Scars","enrollment":14},{"nctId":"NCT01645709","phase":"PHASE1, PHASE2","title":"Safety, Tolerability, and Efficacy of IA Verapamil in the Treatment of Joint Pain in Subjects With Osteoarthritis of the Knee","status":"TERMINATED","sponsor":"Calosyn Pharma, Inc.","startDate":"2012-04","conditions":"Osteoarthritis of the Knee","enrollment":81},{"nctId":"NCT01068847","phase":"PHASE1","title":"Drug Discrimination in Methadone-Maintained Humans Study 3","status":"COMPLETED","sponsor":"University of Arkansas","startDate":"2010-02","conditions":"Drug Dependence","enrollment":9},{"nctId":"NCT00804895","phase":"PHASE2, PHASE3","title":"Cluster Headache Cortivazol Injection (CHCI)","status":"COMPLETED","sponsor":"Assistance Publique - Hôpitaux de Paris","startDate":"2008-12","conditions":"Cluster Headache","enrollment":43},{"nctId":"NCT00733239","phase":"PHASE1","title":"Drug Discrimination in Methadone-Maintained Humans Study 2","status":"COMPLETED","sponsor":"University of Arkansas","startDate":"2008-08","conditions":"Opioid Dependence","enrollment":15},{"nctId":"NCT00593463","phase":"PHASE1","title":"Drug Discrimination in Methadone-Maintained Humans Study 1","status":"COMPLETED","sponsor":"University of Arkansas","startDate":"2006-09","conditions":"Drug Dependence","enrollment":40}],"_emaApprovals":[],"_faersSignals":[{"count":1,"reaction":"PRODUCT PACKAGING CONFUSION"}],"_approvalHistory":[],"publicationCount":62,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":["Verapamil","Calan","Isoptin"],"phase":"marketed","status":"active","brandName":"Verapamil Injection","genericName":"Verapamil Injection","companyName":"Nishtar Medical University","companyId":"nishtar-medical-university","modality":"Small molecule","firstApprovalDate":"","aiSummary":"Verapamil blocks L-type calcium channels in cardiac and vascular smooth muscle, reducing calcium influx and slowing electrical conduction. Used for Supraventricular tachycardia (acute termination and rate control), Atrial fibrillation with rapid ventricular response, Hypertension.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}